Impact of gender on long-term clinical outcomes and major adverse cardiovascular events in patients undergoing percutaneous coronary intervention receiving clopidogrel therapy: A follow-up study.

There are high frequencies of worse clinical outcomes and major cardiovascular events (MACE) reported in women. We aimed to determine that comparable baseline presentation and contemporary percutaneous coronary intervention (PCI) techniques overcome the gender-based differences in MACE at 1 year follow-up study. This prospective cohort study enrolled 288 consecutive acute coronary syndrome patients (ACS) from September 2022 to March 2023 at Kuwait Teaching Hospital, Peshawar, Pakistan. All the enrolled patients were followed for 1 year and MACE were compared between males and females. Data was analyzed using SPSS version 26.0. There were no statistically significant differences observed between demographic factors including age, BMI, and waist (p value > 0.05). Similarly, no significant differences were observed between biochemical parameters in male and females (p value > 0.05). Men were more physically active (p value 0.001). Smoking and snuffing were significantly higher in male then in female (p values < 0.001) while female had higher rate of diabetes mellitus (DM) and hypertension (HTN) with p values < 0.001 and 0.03, respectively. Overall incidence of 1 year MACE was 22% in males while 21.7% in females (p value 1.00). The male gender had less cardiovascular events over time as compared to females. However, the differences were not statistically significant (p-value 0.96). When baseline presentations, PCI techniques, and post PCI medication are identical in patients with ACS, gender does not impact the MACE at 1 year post PCI.